From April 1, 2022 to June 30, 2022, the company has repurchased 0 shares, representing 0% for CNY 0 million. With this, the company has completed the repurchase of 21,587,509 shares, representing 2.07% for CNY 280.92 million under the buyback announced on December 28, 2021.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
21.77 CNY | +2.01% | +2.69% | +17.04% |
Apr. 26 | CR Double-Crane Pharmaceutical's Profit Rises 11% in Q1 as Revenue Grows 2% | MT |
Apr. 26 | CR Double-Crane Pharmaceutical's Unit Gets Nod to Trial New Pain Medication | MT |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+17.04% | 3.07B | |
+21.85% | 546B | |
-4.77% | 359B | |
+16.97% | 323B | |
+5.69% | 290B | |
+13.68% | 234B | |
+3.65% | 198B | |
-11.12% | 194B | |
+8.08% | 167B | |
-3.40% | 157B |
- Stock Market
- Equities
- 600062 Stock
- News China Resources Double-Crane Pharmaceutical Co.,Ltd.
- Tranche Update on China Resources Double-Crane Pharmaceutical Co.,Ltd.'s Equity Buyback Plan announced on December 28, 2021.